VisionGate Inc., an in vitro diagnostics company that has developed the patented Cell-CT®,a 3D cell imaging platform being utilized in early disease detection, recently added three new esteemed business leaders to its Board of Directors. The directors come on board at a pivotal time for VisionGate, as its revolutionary, non-invasive test for the early detection of lung cancer – LuCED® – is poised to enter the market.Continue reading
Author Archive: AZBio
Arizonans in the Spotlight at BIO 2014
Leaders from across Arizona will be sharing insights on stage at BIO 2014 in San Diego.Continue reading
Regents Approve New UA Downtown Phoenix Project
Construction of Biosciences Partnership Building Set to BeginContinue reading
Nationally Noted Physician-Scientist, Health Administrator Dr. Andrew S. Kraft Named Director of the University of Arizona Cancer Center
TUCSON, Ariz. – Andrew S. Kraft, MD, a nationally recognized prostate cancer physician-scientist and cancer center administrator, has been named the Sydney E. Salmon endowed chair and Director of the University of Arizona Cancer Center and Associate Vice President for Oncology Programs for the University of Arizona Health Sciences Center. In addition to his Cancer Center leadership role, Dr. Kraft joins the University as tenured Professor of Medicine in the Department of Medicine, Division of Hematology/Oncology and Senior Associate Dean for Translational Research in the College of Medicine.Continue reading
ABOR announces Rita Cheng as Northern Arizona University presidential finalist
A six-month, nationwide search for the next president of Northern Arizona University culminated today in the announcement of Rita Cheng, chancellor of Southern Illinois University, as the finalist. Cheng has previously served as provost and vice chancellor for academic affairs at University of Wisconsin-Milwaukee. Her previous accomplishments include serving as associate vice chancellor and interim dean of the School of Continuing Education at UMW, and associate vice chancellor for academic affairs at UMW.Continue reading
New therapy for pancreatic cancer patients shows promising results
TGen-Scottsdale Healthcare lead international clinical trials in advance of FDA application for NAPOLI-1Continue reading
ASU receives Gates grant for research in global health
Arizona State University has been awarded a Grand Challenges Explorations grant, an initiative funded by the Bill & Melinda Gates Foundation. Biodesign Institute researcher Shengxi Chen will pursue a global health and innovation project to design a better, next-generation condom.Continue reading
Ventana Medical Systems, Inc. and MedImmune collaborate to develop a custom PD-L1 Assay for immunotherapy clinical trials
Tucson, Ariz., June 4, 2014 – Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune’s MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.Continue reading
Insys Therapeutics Cannabiodol Receives Orphan Drug Status for Lennox-Gastaut syndrome
On June 2, 2014 the FDA designated Insys Therapeutics’ (INSY) cannabidiol an Orphan Drug for the treatment of Lennox-Gastaut syndrome. (See FDA Site) The firm submitted its Type II Drug Master File to the FDA on May29. A copy of the Insys release on the filing is provided below.